New pill aims to tame heart disease inflammation

NCT ID NCT06031844

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 33 times

Summary

This study tested an oral medication called DFV890 in 24 adults with coronary heart disease and high inflammation levels. Participants took the drug daily for 12 weeks to see if it could lower inflammatory markers like IL-6 and IL-18. The goal is to manage heart disease risk, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Excel Medical Clinical Trials LLC

    Boca Raton, Florida, 33434, United States

  • Monument Health Clinical Research

    Rapid City, South Dakota, 57701, United States

  • Novartis Investigative Site

    Montreal, Quebec, H1T 1C8, Canada

  • Triad Clinical Trials LLC

    Greensboro, North Carolina, 27410, United States

  • UF Health Science Center

    Jacksonville, Florida, 32209, United States

  • Universal Research Group LLC

    Tacoma, Washington, 98405, United States

  • Valley Clinical Trials

    Northridge, California, 91325, United States

Conditions

Explore the condition pages connected to this study.